Ryota Hokari
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ryota Hokari has a total of 311 co-authors. Here are the top co-authors by number of shared publications:
Shunsuke Komoto
71 shared publicationsShigeaki Nagao
Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Japan
63 shared publicationsChie Kurihara
Department of Internal Medicine National Defense Medical College Saitama Japan
60 shared publicationsYoshikiyo Okada
Department of Internal Medicine National Defense Medical College Saitama Japan
59 shared publications- Masaaki Higashiyama
Department of Internal Medicine, National Defense Medical College, Saitama, Japan
56 shared publications - Soichiro Miura
The Second Department of Internal Medicine, National Defense Medical College
54 shared publications
Latest Publications
- Open Access
- 13 November 2026
- Published by S. Karger AG in Inflammatory Intestinal Diseases
Sex differences in clinical characteristics of patients with elderly-onset ulcerative colitis: a cross-sectional study
Background: In ulcerative colitis (UC), no obvious sex differences have been observed regarding onset or symptoms; however, female have been reported to experience a longer period before diagnosis is confirmed. In contrast, elderly-onset UC (EOUC) has been reported to have a higher male prevalence, although sex differences in background characteristics, symptoms, disease severity, and treatment methods remain unclear. Methods: We performed a retrospective cross-sectional study using Japanese nationwide inflammatory bowel disease (IBD) registry data between January 2004 and December 2009. Results: A total of 2,876 cases with EOUC were included. Among them, the ratio of male to female patients was high as previously reported. Female patients had a significantly higher rate of individuals receiving long-term care certification, and a higher incidence of family history of IBD. Female patients also exhibited a relatively higher incidence of abdominal pain. However, no clinically significant sex differences were observed in laboratory data, finding of colonoscopy, clinical course, treatment resistance, severity, and extent of lesions, treatment selection, or treatment-related side effects and complications. Conclusions: Some sex differences exist in family history of IBD and symptoms, but no differences were observed in laboratory data, findings of colonoscopy, disease severity, extent of lesions, treatment, or treatment-related side effects. Further investigation is needed to determine the reasons for the higher male prevalence in EOUC cases, as well as recent treatment choices such as antibody agents and their associated side effects.
- 13 November 2026
- Published by S. Karger AG in Inflammatory Intestinal Diseases
Open AccessSex differences in clinical characteristics of patients with elderly-onset ulcerative colitis: a cross-sectional study
Background: In ulcerative colitis (UC), no obvious sex differences have been observed regarding onset or symptoms; however, female have been reported to experience a longer period before diagnosis is confirmed. In contrast, elderly-onset UC (EOUC) has been reported to have a higher male prevalence, although sex differences in background characteristics, symptoms, disease severity, and treatment methods remain unclear. Methods: We performed a retrospective cross-sectional study using Japanese nationwide inflammatory bowel disease (IBD) registry data between January 2004 and December 2009. Results: A total of 2,876 cases with EOUC were included. Among them, the ratio of male to female patients was high as previously reported. Female patients had a significantly higher rate of individuals receiving long-term care certification, and a higher incidence of family history of IBD. Female patients also exhibited a relatively higher incidence of abdominal pain. However, no clinically significant sex differences were observed in laboratory data, finding of colonoscopy, clinical course, treatment resistance, severity, and extent of lesions, treatment selection, or treatment-related side effects and complications. Conclusions: Some sex differences exist in family history of IBD and symptoms, but no differences were observed in laboratory data, findings of colonoscopy, disease severity, extent of lesions, treatment, or treatment-related side effects. Further investigation is needed to determine the reasons for the higher male prevalence in EOUC cases, as well as recent treatment choices such as antibody agents and their associated side effects.
- Open Access
- 28 September 2026
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
Effectiveness, safety, and clinical outcomes of treatment with the oral α4-integrin antagonist carotegrast methyl in patients with active ulcerative colitis: a multicenter observational study (CANAL study)
Background: Carotegrast methyl is an oral α4-integrin antagonist used to induce remission in patients with ulcerative colitis with an inadequate response to 5-aminosalicylate (5-ASA). This multicenter, retrospective observational study evaluated the clinical usefulness of carotegrast methyl in real-world practice. Methods: Patients with an inadequate response to 5-ASA who received carotegrast methyl were included. Clinical data were collected during and after treatment for up to 52 weeks. The primary endpoint was the response rate at week 8. The remission rate at week 8, response/remission rate at end of treatment, cumulative response/remission rate, and adverse drug reactions were also assessed. Effectiveness was evaluated using the patient reported outcomes-2 measure (sum of Mayo subscores for stool frequency and rectal bleeding). Results: Data were collected from 196 patients, of whom 180 were evaluable for effectiveness. The PRO-2-defined response and remission rates at week 8 were 57.8% and 43.3%, respectively, and the rates at the end of treatment (median treatment duration: 83.5 days) were 58.9% and 50.0%, respectively. The cumulative PRO-2-defined response/remission rates increased until week 16, followed by a slight further increase. Adverse drug reactions occurred in 31 of 196 patients (15.8%, 43 events), with no serious events. Conclusions: In terms of patient-reported symptom improvement, carotegrast methyl is an effective and well-tolerated treatment for patients with ulcerative colitis who have an inadequate response to 5-ASA. A substantial proportion of patients responded to 8 weeks of treatment. Continued treatment for up to 16 weeks may improve symptoms, even in patients with insufficient response at week 8.
- 28 September 2026
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
Open AccessEffectiveness, safety, and clinical outcomes of treatment with the oral α4-integrin antagonist carotegrast methyl in patients with active ulcerative colitis: a multicenter observational study (CANAL study)
Background: Carotegrast methyl is an oral α4-integrin antagonist used to induce remission in patients with ulcerative colitis with an inadequate response to 5-aminosalicylate (5-ASA). This multicenter, retrospective observational study evaluated the clinical usefulness of carotegrast methyl in real-world practice. Methods: Patients with an inadequate response to 5-ASA who received carotegrast methyl were included. Clinical data were collected during and after treatment for up to 52 weeks. The primary endpoint was the response rate at week 8. The remission rate at week 8, response/remission rate at end of treatment, cumulative response/remission rate, and adverse drug reactions were also assessed. Effectiveness was evaluated using the patient reported outcomes-2 measure (sum of Mayo subscores for stool frequency and rectal bleeding). Results: Data were collected from 196 patients, of whom 180 were evaluable for effectiveness. The PRO-2-defined response and remission rates at week 8 were 57.8% and 43.3%, respectively, and the rates at the end of treatment (median treatment duration: 83.5 days) were 58.9% and 50.0%, respectively. The cumulative PRO-2-defined response/remission rates increased until week 16, followed by a slight further increase. Adverse drug reactions occurred in 31 of 196 patients (15.8%, 43 events), with no serious events. Conclusions: In terms of patient-reported symptom improvement, carotegrast methyl is an effective and well-tolerated treatment for patients with ulcerative colitis who have an inadequate response to 5-ASA. A substantial proportion of patients responded to 8 weeks of treatment. Continued treatment for up to 16 weeks may improve symptoms, even in patients with insufficient response at week 8.
- Open Access
- 15 September 2026
- Published by Wiley in Pathology International
- Vol. 76 (9) , e70179
Porto‐Sinusoidal Vascular Disorder‐Spectrum Portal Venopathy as a Structural Substrate for Portal Hypertension in Anti‐Centromere Antibody‐Positive Primary Biliary Cholangitis
Anti‐centromere antibody (ACA) positivity in primary biliary cholangitis (PBC) has been associated with a portal hypertension‐dominant clinical trajectory, even without advanced fibrosis. This study investigated whether porto‐sinusoidal vascular disorder (PSVD)‐spectrum portal venopathy may underlie this phenotype. This retrospective case‐series study included three ACA‐positive PBC‐spectrum patients who underwent liver biopsy. The clinical characteristics, imaging findings, liver and spleen stiffness, hepatic venography, and hepatic venous pressure gradient (HVPG) were evaluated. Liver specimens were assessed for PSVD‐spectrum portal venopathy and PBC‐related bile duct injury. All patients presented with PSVD‐spectrum portal venopathy on liver biopsy; PBC‐defining bile duct lesions were present in two patients, and the presence of ductular reaction was suggestive of a biliary disease but not diagnostic for PBC in one patient. All patients had manifestations of portal hypertension with preserved liver synthetic function and noncirrhotic liver stiffness. The portal sandwich sign was present in all patients. When available, spleen stiffness was markedly elevated, indicating spleen–liver stiffness dissociation. HVPG was heterogeneous, with normal values in two patients and marked elevation in one patient. In summary, PSVD‐spectrum portal venopathy may contribute to disproportionate portal hypertension in ACA‐positive PBC‐spectrum patients but constitutes a diagnostic gray zone because PBC is defined as exclusionary in PSVD definitions.
- 15 September 2026
- Published by Wiley in Pathology International
- Vol. 76 (9) , e70179
Open AccessPorto‐Sinusoidal Vascular Disorder‐Spectrum Portal Venopathy as a Structural Substrate for Portal Hypertension in Anti‐Centromere Antibody‐Positive Primary Biliary Cholangitis
Anti‐centromere antibody (ACA) positivity in primary biliary cholangitis (PBC) has been associated with a portal hypertension‐dominant clinical trajectory, even without advanced fibrosis. This study investigated whether porto‐sinusoidal vascular disorder (PSVD)‐spectrum portal venopathy may underlie this phenotype. This retrospective case‐series study included three ACA‐positive PBC‐spectrum patients who underwent liver biopsy. The clinical characteristics, imaging findings, liver and spleen stiffness, hepatic venography, and hepatic venous pressure gradient (HVPG) were evaluated. Liver specimens were assessed for PSVD‐spectrum portal venopathy and PBC‐related bile duct injury. All patients presented with PSVD‐spectrum portal venopathy on liver biopsy; PBC‐defining bile duct lesions were present in two patients, and the presence of ductular reaction was suggestive of a biliary disease but not diagnostic for PBC in one patient. All patients had manifestations of portal hypertension with preserved liver synthetic function and noncirrhotic liver stiffness. The portal sandwich sign was present in all patients. When available, spleen stiffness was markedly elevated, indicating spleen–liver stiffness dissociation. HVPG was heterogeneous, with normal values in two patients and marked elevation in one patient. In summary, PSVD‐spectrum portal venopathy may contribute to disproportionate portal hypertension in ACA‐positive PBC‐spectrum patients but constitutes a diagnostic gray zone because PBC is defined as exclusionary in PSVD definitions.
- 6 August 2025
- Published by Elsevier in Pancreatology
- Vol. 25 (6) , 919-929
Water avoidance stress exacerbates orthotopic pancreatic cancer growth by suppressing cytotoxic T lymphocyte infiltration
- 6 August 2025
- Published by Elsevier in Pancreatology
- Vol. 25 (6) , 919-929
Water avoidance stress exacerbates orthotopic pancreatic cancer growth by suppressing cytotoxic T lymphocyte infiltration
- 1 January 2024
- Published by Springer Nature
- p. 77-84
Diagnostic Algorithm for IBS
- 21 October 2023
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 30 (4) , 343-347
Fulminant necrotizing fasciitis by Edwardsiella tarda in a patient with alcoholic liver cirrhosis: A case report
- 21 October 2023
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 30 (4) , 343-347
Fulminant necrotizing fasciitis by Edwardsiella tarda in a patient with alcoholic liver cirrhosis: A case report
- Open Access
- 9 June 2023
- Published by The Editorial Office of Gut and Liver in Gut and Liver
- Vol. 18 (3) , 465-475
Probiotic Yeast from Miso Ameliorates Stress-Induced Visceral Hypersensitivity by Modulating the Gut Microbiota in a Rat Model of Irritable Bowel Syndrome
Nao Sugihara, Yoshikiyo Okada, Akira Tomioka, Suguru Ito, Rina Tanemoto, Shin Nishii, Akinori Mizoguchi, Kenichi Inaba, Yoshinori Hanawa, Kazuki Horiuchi, Akinori Wada, Yoshihiro Akita, Masaaki Higashiyama, Chie Kurihara, Shunsuke Komoto, Kengo Tomita, Ryota Hokari. Gut and Liver 2024;18:465-75. https://doi.org/10.5009/gnl220100
- 9 June 2023
- Published by The Editorial Office of Gut and Liver in Gut and Liver
- Vol. 18 (3) , 465-475
Open AccessProbiotic Yeast from Miso Ameliorates Stress-Induced Visceral Hypersensitivity by Modulating the Gut Microbiota in a Rat Model of Irritable Bowel Syndrome
Nao Sugihara, Yoshikiyo Okada, Akira Tomioka, Suguru Ito, Rina Tanemoto, Shin Nishii, Akinori Mizoguchi, Kenichi Inaba, Yoshinori Hanawa, Kazuki Horiuchi, Akinori Wada, Yoshihiro Akita, Masaaki Higashiyama, Chie Kurihara, Shunsuke Komoto, Kengo Tomita, Ryota Hokari. Gut and Liver 2024;18:465-75. https://doi.org/10.5009/gnl220100
- 23 June 2022
- Published by Springer Nature
- p. 33-41
Comparison of Pathological and Endoscopic Images (per Organ)
- 23 June 2022
- Published by Springer Nature
- p. 33-41
Comparison of Pathological and Endoscopic Images (per Organ)
- 23 June 2022
- Published by Springer Nature
- p. 131-152
Case-Based Images: Cases with Atypical Clinical Symptoms/Possible Cases
- 23 June 2022
- Published by Springer Nature
- p. 131-152
Case-Based Images: Cases with Atypical Clinical Symptoms/Possible Cases